

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALLIED GROUP LIMITED

(聯合集團有限公司)

(Incorporated in Hong Kong with limited liability)

(Stock Code: 373)

INSIDE INFORMATION

- (1) DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS TO 15TH APRIL 2024;**
- (2) POSTPONEMENT OF BOARD MEETING; AND**
- (3) SUSPENSION OF TRADING**

This announcement is made by the board of directors (the “**Board**”) of Allied Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09(2)(a) and 13.49(3) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 15th March, 2024 in relation to the meeting of the Board scheduled to be held on 27th March, 2024 for the purpose of, among other matters, considering and approving the annual results of the Group for the year ended 31st December, 2023 (the “**2023 Annual Results**”). Reference is also made to the announcement of Tian An China Investments Company Limited (“**TACI**”, a listed subsidiary of the Company) dated 27th March, 2024, in respect of the delay in publication of its annual results announcement for the year ended 31st December, 2023 (the “**TACI’s Announcement**”).

(1) DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS

- i. Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish an announcement for the 2023 Annual Results on a date not later than three months after the end of the financial year of the Company, namely, on or before 31st March, 2024 (the “**Publication**”). Under Rule 13.49(2) of the Listing Rules, the preliminary announcement in relation to the 2023 Annual Results shall be based on the Group’s consolidated financial statements for the financial year ended 31st December, 2023 which shall have been agreed with the Company’s auditors.
- ii. The acquisition of China Medical & HealthCare Group Limited (“**CMH**”) by TACI on 5th October, 2023 (the “**Acquisition**”) requires the consolidation of the audited accounts of CMH under two separate listed companies, firstly into TACI and then into the Company (the “**Consolidations**”). Prior to the Acquisition, CMH was not a subsidiary of another listed company and did not have to prepare a consolidation package, which took the finance team of CMH longer than expected to complete the consolidation packages for both the period ended on the date of the Acquisition and for the year ended at 31st December, 2023. The delay was compounded by the change of auditors by CMH in December 2023.
- iii. The delay in the Publication is caused solely by the time required to complete the two Consolidations.
- iv. As at the date of this announcement, a substantial portion of the information for the purpose of the Consolidations had been provided by CMH. TACI and the Company will work closely with their auditors to finalise the audit of the 2023 Annual Results. As mentioned in the TACI’s Announcement, its audited results for the year ended 31st December, 2023 can be published on 12th April, 2024. Having considered the work required in the Consolidations, and after consulting the auditors of the Company, the Board is of the view that the Publication can be made on 15th April, 2024.

(2) POSTPONEMENT OF BOARD MEETING

The Board announces that due to the delay in publication of the 2023 Annual Results, the meeting of the Board for the purpose of considering and approving, among others, the 2023 Annual Results will be postponed to 15th April, 2024.

(3) SUSPENSION OF TRADING

At the request of the Company, trading in the shares of the Company on the Stock Exchange will be suspended from 9:00 a.m. on 2nd April, 2024 pending the release of the 2023 Annual Results by the Company.

The Board would like to inform shareholders and potential investors of the Company that other than TACI, all other listed subsidiaries (including CMH) of the Company have already announced their respective audited results for the year ended 31st December, 2023.

The Board is confident that the delay in Publication is attributable to an unprecedented and isolated incident. The Board is also confident that after the close collaboration of the various finance teams and auditors of the three companies on the Consolidations in the immediate past, the issues have been resolved and the Board does not foresee any delays in results announcements in the future as a result of the consolidations.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Allied Group Limited
Edwin Lo King Yau
Executive Director

Hong Kong, 27th March, 2024

As at the date of this announcement, the Board comprises Messrs. Lee Seng Hui (Chief Executive), Edwin Lo King Yau and Mak Pak Hung being the Executive Directors; Mr. Arthur George Dew (Chairman), Mr. Akihiro Nagahara (Vice Chairman) and Ms. Lee Su Hwei being the Non-Executive Directors; and Mr. David Craig Bartlett, Mr. Alan Stephen Jones, Ms. Lisa Yang Lai Sum and Mr. Kelvin Chau Kwok Wing being the Independent Non-Executive Directors.